MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease.
dementia with Lewy bodies
iron
mild cognitive impairment
quantitative susceptibility mapping
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
10
04
2021
received:
16
02
2021
accepted:
01
05
2021
pubmed:
26
5
2021
medline:
27
10
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
Neurodegeneration of the substantia nigra in Lewy body disease is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. Our objective was to measure iron deposition in the substantia nigra in patients with probable dementia with Lewy bodies (pDLB) and patients who are at risk for pDLB by quantitative susceptibility mapping (QSM). Participants included pDLB (n = 36), mild cognitive impairment with at least one core feature of DLB (MCI-LB; n = 15), idiopathic rapid eye movement sleep behavior disorder (iRBD; n = 11), and an age-and gender-matched clinically unimpaired control group (n = 102). QSM was derived from multi-echo 3D gradient recalled echo MRI at 3T, and groups were compared on mean susceptibility values of the substantia nigra and its relation to parkinsonism severity. Patients with pDLB had higher susceptibility in the substantia nigra compared to controls (p< 0.001) and MCI-LB (p = 0.043). The susceptibility of substantia nigra showed an increasing trend from controls to iRBD and MCI-LB, and to pDLB (p< 0.001). Parkinsonism severity was not associated with the mean susceptibility in the substantia nigra in the patient groups. Our data suggested that QSM is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in pDLB. The trend of increasing susceptibility from controls to iRBD and MCI-LB, and to pDLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses, independent of parkinsonism severity.
Sections du résumé
BACKGROUND AND PURPOSE
Neurodegeneration of the substantia nigra in Lewy body disease is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. Our objective was to measure iron deposition in the substantia nigra in patients with probable dementia with Lewy bodies (pDLB) and patients who are at risk for pDLB by quantitative susceptibility mapping (QSM).
METHODS
Participants included pDLB (n = 36), mild cognitive impairment with at least one core feature of DLB (MCI-LB; n = 15), idiopathic rapid eye movement sleep behavior disorder (iRBD; n = 11), and an age-and gender-matched clinically unimpaired control group (n = 102). QSM was derived from multi-echo 3D gradient recalled echo MRI at 3T, and groups were compared on mean susceptibility values of the substantia nigra and its relation to parkinsonism severity.
RESULTS
Patients with pDLB had higher susceptibility in the substantia nigra compared to controls (p< 0.001) and MCI-LB (p = 0.043). The susceptibility of substantia nigra showed an increasing trend from controls to iRBD and MCI-LB, and to pDLB (p< 0.001). Parkinsonism severity was not associated with the mean susceptibility in the substantia nigra in the patient groups.
CONCLUSIONS
Our data suggested that QSM is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in pDLB. The trend of increasing susceptibility from controls to iRBD and MCI-LB, and to pDLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses, independent of parkinsonism severity.
Identifiants
pubmed: 34033185
doi: 10.1111/jon.12878
pmc: PMC8440493
mid: NIHMS1730297
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1020-1027Subventions
Organisme : NCRR NIH HHS
ID : C06 RR018898
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG040042
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NIA NIH HHS
ID : R37 AG011378
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Informations de copyright
© 2021 American Society of Neuroimaging.
Références
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Neuroimage. 2018 Apr 15;170:271-282
pubmed: 28536045
J Mol Neurosci. 2008 Jul;35(3):273-81
pubmed: 18491043
Lancet Neurol. 2010 Nov;9(11):1070-7
pubmed: 20846908
Alzheimers Res Ther. 2015 Feb 17;7(1):6
pubmed: 25717349
Magn Reson Imaging. 2015 Jun;33(5):559-65
pubmed: 25721997
Neuroimage. 2012 Sep;62(3):1593-9
pubmed: 22634862
Neuroimage Clin. 2018 May 24;19:683-689
pubmed: 29872633
Hum Mol Genet. 2018 May 1;27(9):1514-1532
pubmed: 29452354
Sleep Med. 2011 May;12(5):445-53
pubmed: 21349763
J Neurol Psychopathol. 1924 Nov;5(19):195-208
pubmed: 21611545
PLoS One. 2016 Sep 06;11(9):e0162460
pubmed: 27598250
Mov Disord. 2019 Jul;34(7):1006-1013
pubmed: 31180615
Behav Neurol. 2018 Jun 5;2018:6929732
pubmed: 29971138
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
BMC Neurosci. 2019 May 22;20(1):23
pubmed: 31117957
Magn Reson Med. 2012 Jan;67(1):137-47
pubmed: 21671269
AJNR Am J Neuroradiol. 2017 Sep;38(9):1737-1741
pubmed: 28705819
Eur J Neurol. 2017 Feb;24(2):357-365
pubmed: 27982501
Magn Reson Med. 2015 Jan;73(1):82-101
pubmed: 25044035
Neurology. 2010 Sep 7;75(10):889-97
pubmed: 20820000
Mov Disord. 2018 Sep;33(9):1432-1439
pubmed: 29756231
Front Aging Neurosci. 2019 May 27;11:106
pubmed: 31191294
Neurobiol Aging. 2015 Jan;36(1):452-61
pubmed: 25128280
Clin Nucl Med. 2015 Jan;40(1):26-31
pubmed: 25426755
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Neurology. 2004 Jan 27;62(2):181-7
pubmed: 14745051
Neuroimage Clin. 2019;24:101999
pubmed: 31539801
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Mov Disord. 2015 Jun;30(7):945-52
pubmed: 25772492
Free Radic Biol Med. 2001 May 15;30(10):1163-70
pubmed: 11369507
Neuroimage. 2011 Apr 15;55(4):1645-56
pubmed: 21224002
J Alzheimers Dis. 2018;64(2):393-404
pubmed: 29865069
Ultrasound Med Biol. 2014 Oct;40(10):2365-71
pubmed: 25194454
Ann N Y Acad Sci. 2010 Jan;1184:15-54
pubmed: 20146689
Neuroradiology. 2017 Jan;59(1):89-98
pubmed: 28035426
Arch Neurol. 1991 Jul;48(7):725-8
pubmed: 1859300
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Magn Reson Imaging. 2015 Jan;33(1):1-25
pubmed: 25267705
JAMA Neurol. 2013 Nov;70(11):1396-402
pubmed: 24042491
Front Neurosci. 2019 Mar 01;13:180
pubmed: 30881284
Mov Disord. 2017 Mar;32(3):441-449
pubmed: 28004859
Mayo Clin Proc. 2019 Aug;94(8):1516-1523
pubmed: 31280871
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
J Biol Chem. 2008 Apr 18;283(16):10992-1003
pubmed: 18258594
J Neurol Sci. 2018 Mar 15;386:46-52
pubmed: 29406966
Cells. 2019 Jan 29;8(2):
pubmed: 30699914
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Opt Lett. 2003 Jul 15;28(14):1194-6
pubmed: 12885018